Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality
- PMID: 17045339
- DOI: 10.1016/j.molimm.2006.09.005
Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality
Abstract
Although it is now clear that certain Fc glycan structures on immunoglobulin G (IgG) antibodies (Abs) can have a dramatic influence on binding to selected Fcgamma receptors (FcgammaR) and on Fc-mediated immune functions, the effects of all known Fc glycan structures still have not been exhaustively studied. We report that in vitro analyses of pairs of monoclonal human IgG Abs that differ in the amount of sialic acid in their Fc glycans revealed that, for each of the three Ab pairs we examined, higher levels of sialylation were associated with reduced activity in Ab-dependent cellular cytotoxicity (ADCC) assays. This relationship between sialylation and ADCC activity was observed regardless of whether the differences in the extent of sialylation were derived by different Ab production processes, use of a lectin column to separate monoclonal Ab preparations into differentially sialylated fractions, or use of direct in vitro glycoengineering methods to convert a lesser sialylated Ab into a highly sialylated Ab. Subsequent investigations revealed that, depending on the individual Ab and how the differences in sialylation were derived, the lower ADCC potency of the more sialylated variants was apparently due to lower-affinity binding to FcgammaRIIIa on natural killer (NK) cells and/or, more interestingly, lower-affinity binding to cell-surface antigen. Our data provide the first example of an Fc glycan structure impacting antigen binding and suggest that avoiding Fc glycan sialylation can offer another means of optimizing ADCC activity of Abs.
Similar articles
-
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.Glycobiology. 2007 Jan;17(1):104-18. doi: 10.1093/glycob/cwl057. Epub 2006 Sep 29. Glycobiology. 2007. PMID: 17012310
-
Terminal sugars of Fc glycans influence antibody effector functions of IgGs.Curr Opin Immunol. 2008 Aug;20(4):471-8. doi: 10.1016/j.coi.2008.06.007. Epub 2008 Jul 17. Curr Opin Immunol. 2008. PMID: 18606225 Review.
-
The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.Biotechnol Bioeng. 2022 Jan;119(1):102-117. doi: 10.1002/bit.27953. Epub 2021 Oct 20. Biotechnol Bioeng. 2022. PMID: 34647616
-
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9. J Immunol Methods. 2011. PMID: 21855548
-
Ig-binding receptors on human NK cells as effector and regulatory surface molecules.Int Rev Immunol. 2001 Jun;20(3-4):371-414. doi: 10.3109/08830180109054414. Int Rev Immunol. 2001. PMID: 11878510 Review.
Cited by
-
Editorial: Structure, isotypes, targets, and post-translational modifications of immunoglobulins and their role in infection, inflammation and autoimmunity, Volume II.Front Immunol. 2022 Oct 17;13:1041613. doi: 10.3389/fimmu.2022.1041613. eCollection 2022. Front Immunol. 2022. PMID: 36325328 Free PMC article. No abstract available.
-
The role of antibody glycosylation in autoimmune and alloimmune kidney diseases.Nat Rev Nephrol. 2024 Oct;20(10):672-689. doi: 10.1038/s41581-024-00850-0. Epub 2024 Jul 3. Nat Rev Nephrol. 2024. PMID: 38961307 Review.
-
Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.Plant Biotechnol J. 2024 May;22(5):1224-1237. doi: 10.1111/pbi.14260. Epub 2023 Dec 4. Plant Biotechnol J. 2024. PMID: 38050338 Free PMC article.
-
MIgGGly (mouse IgG glycosylation analysis) - a high-throughput method for studying Fc-linked IgG N-glycosylation in mice with nanoUPLC-ESI-MS.Sci Rep. 2018 Sep 12;8(1):13688. doi: 10.1038/s41598-018-31844-1. Sci Rep. 2018. PMID: 30209257 Free PMC article.
-
Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.MAbs. 2019 Jan;11(1):129-144. doi: 10.1080/19420862.2018.1530920. Epub 2018 Oct 19. MAbs. 2019. PMID: 30296198 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources